Expert oncologists discuss the evolving treatment landscape in ER+/HER2- Metastatic Breast Cancer.
EP. 1: Treatment Landscape in ER+/HER2- Metastatic Breast Cancer and Unmet Needs
A discussion of the disease state, current therapies, and treatment challenges in ER+/HER2- metastatic breast cancer.
EP. 2: EMERALD Subgroup Analysis in Patients With Visceral and Bone Metastases: Clinical Implication
A comprehensive review of the safety, efficacy, and subgroup analysis of the EMERALD Trial.
EP. 3: Evaluating the Impact of Elacestrant Use in Clinical Practice for Patients With ER+/HER2-Metastasized Breast Cancer
Identifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.
EP. 4: Navigating Endocrine Resistance in the Treatment of ER+/HER2- Metastatic Breast Cancer
Current treatment landscape in ER+/HER2- metastatic breast cancer and unmet needs in overcoming treatment resistance.
EP. 5: EMERALD Subgroup Analysis in Patients with Coexisting PIK3CA and TP53 Mutations
Dr. Hope Rugo discusses EMERALD subgroup analysis, safety, and efficacy in patients with coexisting resistance mutations.
EP. 6: Expert Insights in Overcoming Endocrine Resistance for Patients With ER+/HER2- Metastatic Breast Cancer
Expert insights on improving outcomes in ER+/HER2- metastatic breast cancer patients with resistance mutations.
EP. 7: The Evolving Treatment Landscape in ER+/HER2- Low Metastatic Breast Cancer
Dr. Paolo Tarantino discusses the current treatment landscape of ER+/HER2- low metastatic breast cancer and unmet needs.
EP. 8: EMERALD Subgroup Analysis in HER2-Low Metastatic Breast Cancer: Safety and Efficacy of Elacestrant
A comprehensive review of the safety and efficacy from a HER2-low subgroup analysis in the EMERALD Trial presented at SABCS 2023 and clinical implications in practice.
EP. 9: Elacestrant in Clinical Practice for Patients with ER+/HER2-Low Metastatic Breast Cancer
Dr. Paolo Tarantino offers expert guidance on optimizing outcomes for patients with ER+/HER2-low metastatic breast cancer.
2 Commerce Drive Cranbury, NJ 08512